CAWM
IOVA icon

Capital A Wealth Management’s Iovance Biotherapeutics IOVA Stock Holding History

Capital A Wealth Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-55
Closed -$183 – 634
2025
Q1 		$183 Buy
55
+5
+10% +$26 ﹤0.01% 681
2024
Q4 		$370 Buy
+50
New +$463 ﹤0.01% 685

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital A Wealth Management's IOVA Position: Q2 2025 in Review

Capital A Wealth Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 55 shares — an estimated $183 sold.

Capital A Wealth Management first reported a position in IOVA in Q4 2024 and held it in 2 quarters. The position peaked at $370 in Q4 2024. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Capital A Wealth Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital A Wealth Management sold 55 Iovance Biotherapeutics shares in Q2 2025, an estimated $183.
  • Capital A Wealth Management first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 2 quarters.
  • Capital A Wealth Management's Iovance Biotherapeutics position peaked at $370 in Q4 2024.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Capital A Wealth Management's 13F filing for Q2 2025, filed 26 Sep 2025.